series-c-plus
Stage
2017
Founded
2
Investors
About
GAMAMABS is a French biotechnology company developing innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Its lead product, GM-102, targets the tumor-associated antigen AMHR2 for ovarian and other solid tumors.
Explore GAMAMABS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.